450
The European Medicines Agency (EMA) has approved NovoThirteen (catridecacog) for use within the EU for the long term prophylactic treatment of bleeding in patients with congenital factor XIII A-subunit deficiency, a form of the rare disease hemophilia. For further information, please visit EMA website.